Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) Short Interest Update

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 216,200 shares, a growth of 601.9% from the January 31st total of 30,800 shares. Based on an average trading volume of 2,130,000 shares, the short-interest ratio is currently 0.1 days. Approximately 24.0% of the company’s stock are short sold.

Lipella Pharmaceuticals Stock Down 7.8 %

NASDAQ LIPO opened at $2.94 on Friday. Lipella Pharmaceuticals has a fifty-two week low of $2.21 and a fifty-two week high of $12.00. The business has a 50 day moving average price of $3.16 and a two-hundred day moving average price of $3.18. The stock has a market cap of $3.55 million, a PE ratio of -0.69 and a beta of 0.28.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lipella Pharmaceuticals stock. Virtu Financial LLC acquired a new position in Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 13,310 shares of the company’s stock, valued at approximately $41,000. Virtu Financial LLC owned approximately 1.10% of Lipella Pharmaceuticals at the end of the most recent reporting period. 74.31% of the stock is currently owned by hedge funds and other institutional investors.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).